文献速递肝病

拮抗载脂蛋白J分子伴侣促进mTOR蛋白酶体降解并缓解肝脏脂质沉积

Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition.
PubMed 文献 · Hepatology · 2023-01-03

本研究探讨载脂蛋白J(ApoJ)调控mTOR泛素-蛋白酶体降解的机制,并在非酒精性脂肪性肝病(NAFLD)小鼠中验证ApoJ拮抗肽的作用。发现细胞内ApoJ通过R324残基干扰FBW7与mTOR结合,抑制mTOR泛素化;靶向ApoJ可促进mTOR蛋白酶体降解、恢复脂自噬和溶酶体活性,减少肝脏脂质沉积;拮抗肽(Kd=2.54 µM)改善NAFLD或2型糖尿病小鼠的肝脏病理、血脂血糖稳态及胰岛素敏感性。

要点

  • NAFLD患者肝脏和高脂培养肝细胞中ApoJ上调,肝ApoJ水平与mTOR及自噬标志物相关。
  • 细胞内ApoJ通过R324残基干扰FBW7与mTOR结合,阻止mTOR泛素化。
  • ApoJ拮抗肽(Kd=2.54 µM)改善NAFLD或2型糖尿病小鼠肝脏病理及糖脂代谢。

核心结论

  • ApoJ拮抗肽可能通过恢复mTOR与FBW7相互作用、促进mTOR泛素-蛋白酶体降解,成为脂质相关代谢紊乱的潜在治疗手段。

研究设计与样本

  • 采用组学方法分析高脂培养基喂养的肝细胞和NAFLD患者肝脏中ApoJ表达。
  • 在体外和体内进行功能获得或功能缺失分析,验证靶向ApoJ对mTOR降解和肝脏脂质沉积的影响。
  • 在NAFLD或2型糖尿病小鼠中评估ApoJ拮抗肽的作用。

主要发现

  • 高脂培养基喂养的肝细胞和NAFLD患者肝脏中ApoJ上调,小鼠肝脏ApoJ水平与mTOR及自噬蛋白标志物水平相关,并与肝脏脂质含量正相关。
  • 非分泌的细胞内ApoJ结合mTOR激酶结构域,通过其R324残基干扰FBW7泛素连接酶与mTOR的相互作用,阻止mTOR泛素化。
  • 靶向ApoJ促进mTOR蛋白酶体降解,恢复脂自噬和溶酶体活性,从而防止肝脏脂质沉积。
  • ApoJ拮抗肽(解离常数Kd=2.54 µM)与应激诱导的ApoJ相互作用,改善NAFLD或2型糖尿病小鼠的肝脏病理、血清脂质和血糖稳态及胰岛素敏感性。

关键数值与推荐

  • ApoJ拮抗肽的解离常数(Kd)为2.54 µM。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Overnutrition-induced activation of mammalian target of rapamycin (mTOR) dysregulates intracellular lipid metabolism and contributes to hepatic lipid deposition. Apolipoprotein J (ApoJ) is a molecular chaperone and participates in pathogen-induced and nutrient-induced lipid accumulation. This study investigates the mechanism of ApoJ-regulated ubiquitin-proteasomal degradation of mTOR, and a proof-of-concept ApoJ antagonist peptide is proposed to relieve hepatic steatosis. APPROACH AND RESULTS: By using omics approaches, upregulation of ApoJ was found in high-fat medium-fed hepatocytes and livers of patients with NAFLD. Hepatic ApoJ level associated with the levels of mTOR and protein markers of autophagy and correlated positively with lipid contents in the liver of mice. Functionally, nonsecreted intracellular ApoJ bound to mTOR kinase domain and prevented mTOR ubiquitination by interfering FBW7 ubiquitin ligase interaction through its R324 residue. In vitro and in vivo gain-of-function or loss-of-function analysis further demonstrated that targeting ApoJ promotes proteasomal degradation of mTOR, restores lipophagy and lysosomal activity, thus prevents hepatic lipid deposition. Moreover, an antagonist peptide with a dissociation constant (Kd) of 2.54 µM interacted with stress-induced ApoJ and improved hepatic pathology, serum lipid and glucose homeostasis, and insulin sensitivity in mice with NAFLD or type II diabetes mellitus. CONCLUSIONS: ApoJ antagonist peptide might be a potential therapeutic against lipid-associated metabolic disorders through restoring mTOR and FBW7 interaction and facilitating ubiquitin-proteasomal degradation of mTOR.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Duan S, Qin N, Pi J, et al. Antagonizing apolipoprotein J chaperone promotes proteasomal degradation of mTOR and relieves hepatic lipid deposition. Hepatology. 2023. PMID: 37013405. doi:10.1097/HEP.0000000000000185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。